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a b s t r a c t
We report a single institution experience with total lung irradiation in 53 metastatic bone sarcoma
patients in the context of two young female patients who died from treatment-induced pulmonary
toxicity. A radiation dose of 19.5 Gy in 1.5 Gy daily fractions was given as two opposing ﬁelds with a
conventional technique. Both patients succumbed within 3 months following radiotherapy. One patient
had osteosarcoma whereas the other advanced Ewing's sarcoma; both with widespread metastases to
the lungs at primary diagnosis. In retrospect, most likely high dose methotrexate lung toxicity observed
in the osteosarcoma patient, and the GI-toxicity following pelvic radiotherapy in Ewing's case, both
observed during the initial phase of their multimodal treatment, might indicate an increased individual
radiosensitivity.
In view of this, a review of our experience in 53 bone sarcoma patients (19 with Ewing's sarcoma and
34 with osteosarcoma) treated at our institution was conducted. We have not previously experienced
signiﬁcant toxicity following total lung irradiation. Among these, 42% (8/19) with Ewing's sarcoma and
9% (3/34) with osteosarcoma are long-term survivors and without clinically signiﬁcant lung toxicity.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Two comprehensive reviews have addressed total lung irradia-
tion (TLI) in patients with metastases from osteo- and Ewing's
sarcoma [1,2]; a technique that has been used for decades and
presented in textbooks [3,4]. Such radiotherapy involves parallel
opposing anteroposterior/posterioranterior ﬁelds encompassing
the apices and distal costo-phrenic sinuses of both thoracic
cavities. The two lungs may be treated simultaneously or sequen-
tially. Several non-randomized studies have been reported [5–7].
Bilateral lung irradiation might, theoretically, combat microme-
tastases within the lungs and subsequently prevent overt metas-
tases to develop. We have not identiﬁed studies adequately
addressing whether TLI might beneﬁt patients with macroscopic
metastases.
Radiation pneumonitis was ﬁrst described in 1922 by Groover
et al. [8]. To our knowledge, the literature lacks information about
lethal toxicity following such treatment. The tolerance of the lungs
to radiation depends on the volume treated, total dose and dose
per fraction [9,10]. Lung tissues poorly tolerate high-dose irradia-
tion [11]. The fundamental problem with TLI is that pulmonary
parenchymal tolerance to radiation is exceeded before sound
tumoricidal doses are achieved [1]. During treatment planning,
the general recommendation is to not exceed a total dose of
18–20 Gy in 1.5–2.0 Gy daily fractions administered over 2 weeks
in order to respect lung tolerance [1]. For children and young
adults under the age of 15 the standard total dose is 15 Gy.
Here we present two clinical cases demonstrating that even lethal
lung toxicity may occur after TLI. A brief synopsis of the literature is
also presented. We have also, retrospectively, reviewed our single
institution experiences involving 53 bone sarcoma patients treated
with TLI from 1980 to 2012.
2. Clinical material
2.1. Case 1
A female patient, 17 years of age, was admitted for pain in her
left calf, and x-ray revealed a sclerotic lesion in the proximal tibia.
Biopsy was performed and histology showed an osteoblastic
osteosarcoma of high-grade malignancy. At the time of primary
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diagnosis, CT scans of the lungs showed multiple and bilateral lung
metastases; about 25 lesions in the right lung and 14 in the left.
She had an allergic reaction with breathing-difﬁculties follow-
ing intravenous contrast medium administration during the ﬁrst
CT scan.
Chemotherapy: The ﬁrst cycle with doxorubicin/cisplatin and
the subsequent high dose methotrexate (MTX) were given without
complications. However, during the next high dose MTX cycle, she
experienced right-sided thoracic pain at inspiration and bilateral
pleural exudates, as well as skin rash. Pleural drainage was
necessary to prevent serious atelectasis and MTX was eliminated
normally as evaluated by serum measurements. During the fol-
lowing weeks the lung impairment continued. The next cycle of
doxorubicin/cisplatin had to be postponed 3 weeks due to lung
toxicity. Hence MTX was omitted from further treatment. She
received a total of 13 chemotherapy cycles (Fig. 1) based on the
schedule in the EURAMOS-1 protocol [12]. She developed neutro-
penic fever and thrombocytopenia after most cycles. At week 28, a
new MRI and CT scan showed progression of her primary tumor as
well as the lung metastases. However, her subjective lung function
had improved.
Radiotherapy: Five weeks after the last chemotherapy cycle
TLI was started. She received 1.5 Gy13 – total dose 19.5 Gy
(5 fractions per week). She also had irradiation of her primary
tumor in the left tibia, 2.0 Gy30 – total dose 60.0 Gy (5 fractions
per week). To boost the dose from external radiotherapy she
received the bone-seeking radiopharmaceutical 153Sm-EDTMP
[13–18]. This was based on bone-scintigraphy showing that her
primary tumor displayed an avid phenotype. The approved dose of
1 mCi/kg used for pain palliation of osteoblastic skeletal metas-
tases was infused intravenously. Only one dose was administered –
given at day 2 of the TLI.
Clinical course: On day 11 she developed shortness of breath. CT
revealed extensive ground-glass opacities, progressing to involve
the entire lung parenchyma. Underlying infection was ruled out.
She developed severe dyspnea diagnosed as radiation-induced
lung pneumonitis, that progressed over two months following
lung irradiation (Fig. 2). Despite ventilator support with high
oxygen supply at an intensive care unit and high doses of solu-
cortef, 100 mg three times a day, the situation did not improve.
She died about 3 weeks later. Autopsy was not performed.
2.2. Case 2
The other patient, 18 year old female, presented with a 58 cm
tumor located in the right ala ossis ilii, with inﬁltrating growth into
the iliopsoas and gluteus minimus muscles. She had small metas-
tases in both lungs; about 13 lesions in her right and seven in her
left. Biopsy showed a typical Ewing's sarcoma that was conﬁrmed
by the presence of EWS-FL11 fusion transcript. She had a previous
history of mild asthma symptoms, but without the need for
medication. The intended treatment plan was ISG/SSG IV – an
Italian Sarcoma Group/Scandinavian Sarcoma Group Ewing's pro-
tocol [19].
Chemotherapy: She received seven cycles in total (Fig. 3). After
six cycles without complications, she was operated with a pelvic
resection. The pathological examination of the removed tumor
showed a histologically necrotic tumor. A marginal resection
margin was achieved. However, the histological tumor response
was poor (grade I, Picci grading system) [20]. Postoperatively, she
had pain in the right pelvis and leg. An abscess was diagnosed in
relation to the operation cavity, successfully treated with drainage
and antibiotics.
Radiotherapy: One month after surgery she had recovered and
commenced iliac ﬁeld radiotherapy including the tumor bed with
2 cm margins. Hyperfractionated radiotherapy was given, 1.5 Gy
twice daily to a total dose of 40.5 Gy (of planned 42 Gy, 10
fractions per week), employing a three-ﬁeld technique. Concomi-
tant with radiotherapy the seventh cycle was given according to
the protocol mentioned above (Fig. 3). Seven days after radio-
therapy she became neutropenic and developed symptoms of
ileus. Surgery was necessary and demonstrated a perforation most
likely based on radiation induced changes in the small intestine.
Repeated surgical interventions during the next months were
necessary to stabilize the situation with abscesses; resulting in
an ileostomy and weeks with intensive treatment. She had a
severe and protracted postoperative course, necessitating 5 weeks
with ventilator support. Due to the serious toxicity, further
cytostatic treatment was omitted.
Clinical course: Nineteen weeks after the last surgery, her
general condition had recovered. The lung metastases were not
visible by chest CT at this point, but due to overt metastases at
primary diagnosis, we decided to give TLI as consolidation treat-
ment, 19.5 Gy (1.5 Gy13).
Two months after total lung irradiation she was admitted to the
intensive care unit for pneumonia which progressed rapidly
despite various antibiotics. She developed acute respiratory dis-
tress syndrome with typical ground-glass opacities and pleural
effusions on chest CT. Her lung problems progressed, resulting in
the need for ventilator support and high doses of steroids, albeit
with no effect. She died 2 months after total lung irradiation.
Autopsy was not performed.
2.3. Radiotherapy treatment technique for Cases 1 and 2
Both patients were treated with TLI using parallel opposing
ﬁelds. Both treatment plans also included additional smaller ﬁeld
segments to improve dose homogeneity (Figs. 4 and 5).
Beam energy was 15 MV on all ﬁelds for the 18 year old patient,
while the 17 year old patient was treated using 6 MV on the main
opposing ﬁelds, and 15 MV for the segments.
The dose was calculated in Masterplan v.3.3 (Nucletron – an
Elekta company, Veenendaal, The Netherlands) using the collapsed
cone algorithm on CT images with 2.5 mm slice thickness. Mean
bilateral lung dose was normalized to 19.5 Gy in 13 fractions, treated
Fig. 1. Chemotherapy given to patient 1 – modiﬁed EURAMOS-1 regime.
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2 weeks before radiotherapy
2 months after start of total lung irradiation
2 months and 3 weeks after total lung irradiation
Fig. 2. Chest CT of patient 1.
Fig. 3. Chemotherapy given to patient 2 – modiﬁed according to ISG-SSG IV.
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5 days per week. Entrance doses measured in vivo corresponded
well with planned doses for both patients.
Dose statistics for bilateral lungs in patient 1, D98¼19.1 Gy,
2 ccm of the lungs receiving 421.4 Gy. For patient 2,
D98¼19.1 Gy, 2 ccm of the lungs receiving 420.4 Gy.
2.4. Total lung irradiation at the Norwegian Radium Hospital
From 1980 to 2012, 204 patients (including all cancer diagnoses
and all ages) were treated with TLI for lung metastases at
the Norwegian Radium Hospital (1.5 Gy9–15; total doses of
Fig. 5. Treatment portals in patient 2.
Fig. 4. Treatment portals in patient 1.
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13.5–22.5 Gy). Our institution's Sarcoma Database identiﬁed 53 of
these patients; 19 with Ewing's sarcoma and 34 with osteosar-
coma. Some patients (six of 53) had lower doses than intended
due to disease progression, a few had higher doses due to
compensation for interruptions during radiotherapy. As expected,
the majority of the patients died due to rapid progression of their
sarcoma metastases. Importantly, 11 patients were long term
survivors, eight patients with Ewing's sarcoma and three with
osteosarcoma (Table 1). Eight of these patients had long-term
follow-up at our institution.
3. Discussion
TLI is regarded as a well-tolerated, simple procedure with few
acute or late clinical sequelae reported. However, pulmonary
irradiation as a therapeutic modality for metastatic bone sarcomas
is, although introduced 30 years ago, insufﬁciently evaluated to
clearly determine its beneﬁts [1,3,4].
Pneumonitis has been reported after TLI in Ewing's sarcoma
[21], but no serious toxicity like we reported in these two patients
has previously been presented [1,6,7].
The radiation treatments in our patients were audited internally
at our institution, but no abnormalities found. When retrospectively
comparing the clinical courses of these two young girls, they were
both under 20 years of age and had considerable toxicity during
chemotherapy. They were both treated with 19.5 Gy (13 fractions)
to their total lung volume. This is according the generally accepted
total lung tolerance to radiation [1,6,7].
In Case 1, we cannot rule out a contribution from the radiation
of electrons emitted from Quadramet 153Sm-EDTMP. However, the
track-length of these electrons is very short and lung toxicity has
not been reported among groups of osteosarcoma patients given
up to as much as 30 times the injected amount given to our patient
[13–18].
Our experiences with TLI over three decades have not revealed
either serious acute or late toxic effects as experienced in these
two patients. However, the majority of the patients died due to
progression of lung metastases, 1–6 months after TLI.
Table 1







Lung surgery Year of TLI Last follow upa
Osteosarcoma 1981 Nob 2 Yes, prior to TLI 1986 2010
Osteosarcoma 1981 Noc 1 Yes, prior to TLI 1984 2011
Osteosarcoma 1991 Yes 2 Yes, prior to TLI 1992 2009
Ewing sarcoma 1996 Yes 410 No 1997 2012
Ewing sarcoma 1997 Yes 410 Yes, after TLI 1998 2011
Ewing sarcoma 1998 Yes 2 No 1999 2012
Ewing sarcoma 1998 Yes 1 No 1999 2011
Ewing sarcoma 2003 Yes 410 No 2004 2012
Ewing sarcoma 2004 Yes 1 No 2005 2009
Ewing sarcoma 2010 Yes 410 No 2011 2012
Ewing sarcoma 2011 Yes 410 No 2012 2012
a The Sarcoma Database at the Norwegian Radium Hospital is linked to the Cause of Death register in Norway.
b After 5 years.
c After 2 years.
Fig. 6. Bone sarcoma patients treated with total lung irradiation.
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Among the 39 patients that subsequently succumbed to their
disease (Fig. 6). We have no information in their medical records
indicating lung or heart toxicity due to the chemotherapy or
radiotherapy given. One patient committed suicide.
In the 42% (8/19) with Ewing's sarcoma and 9% (3/34) of
the osteosarcoma who were long-term survivors, no clinically
signiﬁcant lung or heart toxicity were documented, although lung
function tests were not performed (Table 1). Interestingly, all three
osteosarcoma patients still alive received TLI following complete
metastatic surgical removal of visible metastases. In fact they all
have fewer metastases and two of them without overt metastases
at diagnosis. Hence, the contribution of TLI is questionable.
The cytostatic drugs given to our two patients (Figs. 1 and 3)
are not known to give pulmonary side effects except for MTX. The
latter may cause pneumonitis, pulmonary ﬁbrosis, interstitial
pneumonia and pleural effusion [22,23]. Additive effects might
be expected combined with lung irradiation [24,25]. In our two
patients, TLI was given 5 weeks and 19 weeks after chemotherapy,
respectively. We do not know if the pulmonary function was
reduced before irradiation since spirometry was not performed.
We cannot rule out that our two patients, who succumbed, had
a genetic predisposition of an individual vulnerability for an
abnormal lung toxicity of radiotherapy. A blood test was per-
formed in Case 2 to look for a mutation in the ataxia telangiectasia
mutated gene, which is associated with a higher sensitivity to
radiation [26]. The mutation was not found. Obviously, we cannot
leave out the possibility of other mutations associated with side-
effects of irradiation [27,28].
4. Conclusion
Lung metastases remain the most common cause of death in
osteosarcoma and Ewing's sarcoma patients. The two cases pre-
sented here demonstrate that lethal lung toxicity may occur
following TLI. In any multimodal treatment regiments, pulmonary
function should be evaluated before TLI. Impairment of pulmonary
function before radiotherapy seems to be a risk factor for higher
grade of late toxicity to the lung [24,29]. Hence, if reduced lung
function is observed, this indicates that TLI probably should be
omitted.
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